WO2001067890A2 - Composition and method to treat weight gain and obesity attributable to psychotropic drugs - Google Patents
Composition and method to treat weight gain and obesity attributable to psychotropic drugs Download PDFInfo
- Publication number
- WO2001067890A2 WO2001067890A2 PCT/US2001/006637 US0106637W WO0167890A2 WO 2001067890 A2 WO2001067890 A2 WO 2001067890A2 US 0106637 W US0106637 W US 0106637W WO 0167890 A2 WO0167890 A2 WO 0167890A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- acid
- carbohydrate
- serotonin
- subject
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 107
- 238000000034 method Methods 0.000 title claims abstract description 24
- 229940001470 psychoactive drug Drugs 0.000 title claims abstract description 24
- 239000004089 psychotropic agent Substances 0.000 title claims abstract description 24
- 230000004584 weight gain Effects 0.000 title claims description 24
- 235000019786 weight gain Nutrition 0.000 title claims description 24
- 208000008589 Obesity Diseases 0.000 title description 7
- 235000020824 obesity Nutrition 0.000 title description 7
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 59
- 235000013305 food Nutrition 0.000 claims abstract description 30
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 26
- 235000011888 snacks Nutrition 0.000 claims abstract description 21
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 18
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 claims abstract description 17
- 229940000681 5-hydroxytryptophan Drugs 0.000 claims abstract description 12
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 claims abstract description 12
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims abstract description 7
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229960003987 melatonin Drugs 0.000 claims abstract description 7
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 83
- 235000014633 carbohydrates Nutrition 0.000 claims description 57
- 229940076279 serotonin Drugs 0.000 claims description 37
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 19
- 239000008121 dextrose Substances 0.000 claims description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- 229920002472 Starch Polymers 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 239000008107 starch Substances 0.000 claims description 12
- 235000019698 starch Nutrition 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 8
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid group Chemical group C(CCCCC(=O)O)(=O)O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 8
- 239000000835 fiber Substances 0.000 claims description 7
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 6
- 239000005913 Maltodextrin Substances 0.000 claims description 6
- 229920002774 Maltodextrin Polymers 0.000 claims description 6
- 229920000881 Modified starch Polymers 0.000 claims description 6
- 235000011054 acetic acid Nutrition 0.000 claims description 6
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 6
- 229940024606 amino acid Drugs 0.000 claims description 6
- 235000011087 fumaric acid Nutrition 0.000 claims description 6
- 239000000543 intermediate Substances 0.000 claims description 6
- 239000001630 malic acid Substances 0.000 claims description 6
- 235000011090 malic acid Nutrition 0.000 claims description 6
- 229940035034 maltodextrin Drugs 0.000 claims description 6
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 5
- 229920001353 Dextrin Polymers 0.000 claims description 5
- 239000004375 Dextrin Substances 0.000 claims description 5
- 235000010323 ascorbic acid Nutrition 0.000 claims description 5
- 239000011668 ascorbic acid Substances 0.000 claims description 5
- 229960005070 ascorbic acid Drugs 0.000 claims description 5
- 235000019425 dextrin Nutrition 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 4
- 239000001361 adipic acid Substances 0.000 claims description 4
- 235000011037 adipic acid Nutrition 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 4
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 4
- 235000015165 citric acid Nutrition 0.000 claims description 4
- 239000002934 diuretic Substances 0.000 claims description 4
- 230000037406 food intake Effects 0.000 claims description 4
- 239000001530 fumaric acid Substances 0.000 claims description 4
- 229930182830 galactose Natural products 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 230000002611 ovarian Effects 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 239000011975 tartaric acid Substances 0.000 claims description 4
- 235000002906 tartaric acid Nutrition 0.000 claims description 4
- 229940030606 diuretics Drugs 0.000 claims description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- 230000001882 diuretic effect Effects 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 229960004799 tryptophan Drugs 0.000 abstract description 19
- 238000011282 treatment Methods 0.000 abstract description 17
- 230000002265 prevention Effects 0.000 abstract description 4
- 208000021017 Weight Gain Diseases 0.000 description 19
- 239000003814 drug Substances 0.000 description 16
- 229940079593 drug Drugs 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 10
- -1 but not limited to Chemical class 0.000 description 10
- 239000002243 precursor Substances 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 7
- 239000003925 fat Substances 0.000 description 7
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 229940020965 zoloft Drugs 0.000 description 7
- GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 description 6
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 6
- 239000000935 antidepressant agent Substances 0.000 description 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 230000004580 weight loss Effects 0.000 description 6
- 206010056465 Food craving Diseases 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 5
- 239000001961 anticonvulsive agent Substances 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000036651 mood Effects 0.000 description 5
- 229960002888 oxitriptan Drugs 0.000 description 5
- 229940035613 prozac Drugs 0.000 description 5
- 230000005062 synaptic transmission Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 4
- XJJZQXUGLLXTHO-ZETCQYMHSA-N (2S)-1-(6-chloro-5-fluoroindol-1-yl)-propan-2-amine Chemical compound FC1=C(Cl)C=C2N(C[C@@H](N)C)C=CC2=C1 XJJZQXUGLLXTHO-ZETCQYMHSA-N 0.000 description 4
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 229960004597 dexfenfluramine Drugs 0.000 description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 4
- 229910052744 lithium Inorganic materials 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000002295 serotoninergic effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 4
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 4
- CJAWPFJGFFNXQI-UHFFFAOYSA-N 2-chloro-6-(1-piperazinyl)pyrazine Chemical compound ClC1=CN=CC(N2CCNCC2)=N1 CJAWPFJGFFNXQI-UHFFFAOYSA-N 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 239000003693 atypical antipsychotic agent Substances 0.000 description 3
- 229940127236 atypical antipsychotics Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 229960004170 clozapine Drugs 0.000 description 3
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 3
- 229960003920 cocaine Drugs 0.000 description 3
- 229940075925 depakote Drugs 0.000 description 3
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 235000021472 generally recognized as safe Nutrition 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 229960005017 olanzapine Drugs 0.000 description 3
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000001242 postsynaptic effect Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 3
- 229960000604 valproic acid Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
- BYTRZQOWWRJDMZ-ZETCQYMHSA-N (2s)-1-(2-chloro-5-fluoroindol-1-yl)propan-2-amine Chemical compound FC1=CC=C2N(C[C@@H](N)C)C(Cl)=CC2=C1 BYTRZQOWWRJDMZ-ZETCQYMHSA-N 0.000 description 2
- SACMXZDUZMBKSI-GYDOPSIJSA-N (e)-but-2-enedioic acid;(2s)-1-(4,4,7-trimethylindeno[1,2-b]pyrrol-1-yl)propan-2-amine Chemical compound OC(=O)\C=C\C(O)=O.C12=CC(C)=CC=C2C(C)(C)C2=C1N(C[C@@H](N)C)C=C2 SACMXZDUZMBKSI-GYDOPSIJSA-N 0.000 description 2
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 2
- VHFVKMTVMIZMIK-UHFFFAOYSA-N 1-(3-chlorophenyl)piperazine Chemical compound ClC1=CC=CC(N2CCNCC2)=C1 VHFVKMTVMIZMIK-UHFFFAOYSA-N 0.000 description 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 2
- DBGIVFWFUFKIQN-SECBINFHSA-N Levofenfluramine Chemical compound CCN[C@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-SECBINFHSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 2
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229960000836 amitriptyline Drugs 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 230000003556 anti-epileptic effect Effects 0.000 description 2
- 239000000228 antimanic agent Substances 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 208000028683 bipolar I disease Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- 235000019788 craving Nutrition 0.000 description 2
- 229960002069 diamorphine Drugs 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 229960002870 gabapentin Drugs 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 description 2
- 229960004801 imipramine Drugs 0.000 description 2
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 208000019906 panic disease Diseases 0.000 description 2
- 229960002296 paroxetine Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960001534 risperidone Drugs 0.000 description 2
- 229940099204 ritalin Drugs 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000000697 serotonin reuptake Effects 0.000 description 2
- 235000021309 simple sugar Nutrition 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940005605 valeric acid Drugs 0.000 description 2
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- LLWYXGZWWWNKKJ-RGSQJGBCSA-N (2s)-2-[[(2s)-2-amino-3-(5-hydroxy-1h-indol-3-yl)propanoyl]amino]butanedioic acid;trihydrate Chemical compound O.O.O.C1=C(O)C=C2C(C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O)=CNC2=C1 LLWYXGZWWWNKKJ-RGSQJGBCSA-N 0.000 description 1
- MOFGVUQTFJGNSG-LBPRGKRZSA-N (2s)-2-acetamido-3-(5-hydroxy-1h-indol-3-yl)propanoic acid Chemical compound C1=C(O)C=C2C(C[C@H](NC(=O)C)C(O)=O)=CNC2=C1 MOFGVUQTFJGNSG-LBPRGKRZSA-N 0.000 description 1
- YWNMBFXNRAQXHP-KRWDZBQOSA-N (2s)-3-(5-hydroxy-1h-indol-3-yl)-2-(phenylmethoxycarbonylamino)propanoic acid Chemical compound N([C@@H](CC=1C2=CC(O)=CC=C2NC=1)C(=O)O)C(=O)OCC1=CC=CC=C1 YWNMBFXNRAQXHP-KRWDZBQOSA-N 0.000 description 1
- OZIWRHKRMMZRKP-XHBSWPGZSA-N (5as,6ar,9r)-7-methyl-9-(methylsulfanylmethyl)-5,5a,6,6a,8,9-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C1NC2=CC=CC3=C2[C@@H]1C[C@H]1N(C)C[C@H](CSC)C=C13 OZIWRHKRMMZRKP-XHBSWPGZSA-N 0.000 description 1
- FQTIRZGRPVLRMG-SPYBWZPUSA-N (5as,6ar,9r)-7-methyl-9-(pyridin-2-ylsulfanylmethyl)-5,5a,6,6a,8,9-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C([C@H]1CN([C@H]2C(C=3C=CC=C4NC[C@H](C=34)C2)=C1)C)SC1=CC=CC=N1 FQTIRZGRPVLRMG-SPYBWZPUSA-N 0.000 description 1
- PCXDSVMGNSSSQR-PBFPGSCMSA-N (5as,6ar,9r)-9-methyl-7-propyl-5,5a,6,6a,8,9-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C1NC2=CC=CC3=C2[C@@H]1C[C@@H]1C3=C[C@@H](C)CN1CCC PCXDSVMGNSSSQR-PBFPGSCMSA-N 0.000 description 1
- RSTKLPZEZYGQPY-UHFFFAOYSA-N 3-(indol-3-yl)pyruvic acid Chemical compound C1=CC=C2C(CC(=O)C(=O)O)=CNC2=C1 RSTKLPZEZYGQPY-UHFFFAOYSA-N 0.000 description 1
- GLQPTZAAUROJMO-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)benzaldehyde Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=C(C=O)C=C1 GLQPTZAAUROJMO-UHFFFAOYSA-N 0.000 description 1
- FGBFEFJZYZDLSZ-UHFFFAOYSA-N 5,7-dimethoxy-2,3-dimethyl-2,3-dihydroinden-1-one Chemical compound COC1=CC(OC)=CC2=C1C(=O)C(C)C2C FGBFEFJZYZDLSZ-UHFFFAOYSA-N 0.000 description 1
- AWFDCTXCTHGORH-HGHGUNKESA-N 6-[4-[(6ar,9r,10ar)-5-bromo-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carbonyl]piperazin-1-yl]-1-methylpyridin-2-one Chemical compound O=C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC(Br)=C(C=34)C2)C1)C)N(CC1)CCN1C1=CC=CC(=O)N1C AWFDCTXCTHGORH-HGHGUNKESA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 206010013486 Distractibility Diseases 0.000 description 1
- JCDZXDWMCKMXFF-UHFFFAOYSA-N Ergolide Natural products CC1CC2OC(=O)C(=C)C2C(OC(C)=O)C2(C)C(=O)CCC12 JCDZXDWMCKMXFF-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GRSZFWQUAKGDAV-KQYNXXCUSA-L IMP(2-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])([O-])=O)O[C@H]1N1C(N=CNC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-L 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- KLPWJLBORRMFGK-UHFFFAOYSA-N Molindone Chemical compound O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 KLPWJLBORRMFGK-UHFFFAOYSA-N 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- MOFGVUQTFJGNSG-UHFFFAOYSA-N Nalpha-Acetyl-5-hydroxy-tryptophan Natural products C1=C(O)C=C2C(CC(NC(=O)C)C(O)=O)=CNC2=C1 MOFGVUQTFJGNSG-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010029897 Obsessive thoughts Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 102000057288 Tryptophan 2,3-dioxygenases Human genes 0.000 description 1
- 108700016257 Tryptophan 2,3-dioxygenases Proteins 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- YEUJZVSROBECPL-UEKVPHQBSA-N [(5as,6ar,9r)-7-methyl-5,5a,6,6a,8,9-hexahydro-4h-indolo[4,3-fg]quinoline-9-yl]methanol Chemical compound C1NC2=CC=CC3=C2[C@@H]1C[C@@H]1C3=C[C@@H](CO)CN1C YEUJZVSROBECPL-UEKVPHQBSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 229940025141 anafranil Drugs 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 229940124604 anti-psychotic medication Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 235000012791 bagels Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 208000025307 bipolar depression Diseases 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- 235000020289 caffè mocha Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229960001564 clomipramine hydrochloride Drugs 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940028937 divalproex sodium Drugs 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229940098766 effexor Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 229940011681 elavil Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- JCDZXDWMCKMXFF-MMLVVLEOSA-N ergolide Chemical compound C[C@@H]1C[C@@H]2OC(=O)C(=C)[C@H]2[C@H](OC(C)=O)[C@]2(C)C(=O)CC[C@@H]12 JCDZXDWMCKMXFF-MMLVVLEOSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- WKGXYQFOCVYPAC-UHFFFAOYSA-N felbamate Chemical compound NC(=O)OCC(COC(N)=O)C1=CC=CC=C1 WKGXYQFOCVYPAC-UHFFFAOYSA-N 0.000 description 1
- 229960003472 felbamate Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000389 fluoxetine hydrochloride Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000011194 good manufacturing practice Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 208000011819 intense anxiety Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960001078 lithium Drugs 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 229960000423 loxapine Drugs 0.000 description 1
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000020166 milkshake Nutrition 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960004938 molindone Drugs 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000006855 networking Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229940072228 neurontin Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QZYYPQAYSFBKPW-UHFFFAOYSA-N org 12962 Chemical compound N1=C(Cl)C(C(F)(F)F)=CC=C1N1CCNCC1 QZYYPQAYSFBKPW-UHFFFAOYSA-N 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- UWCVGPLTGZWHGS-ZORIOUSZSA-N pergolide mesylate Chemical compound CS(O)(=O)=O.C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 UWCVGPLTGZWHGS-ZORIOUSZSA-N 0.000 description 1
- 229960001511 pergolide mesylate Drugs 0.000 description 1
- 229960004526 piracetam Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000009643 reducing diet Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 229940127222 serotonin uptake blocker Drugs 0.000 description 1
- 229960003660 sertraline hydrochloride Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical class O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940074158 xanax Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L9/00—Puddings; Cream substitutes; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates generally to novel therapeutic compositions comprising carbohydrate blends and to methods of using the foregoing for the treatment of weight gain and obesity attributable to the use of psychotropic drugs or to combat weight gain due to the withdrawal from psychotropic drugs.
- the amino acid tryptophan is the precursor to serotonin synthesis in the brain.
- Certain carbohydrates when ingested can increase the ratio of tryptophan to large neutral amino acids (T.LNAA) in the blood stream. This increase of T.LNAA allows a higher level of tryptophan to enter the brain, which is necessary for increasing serotonin synthesis.
- carbohydrates from normal food can shift this T:LNAA ratio to a limited extent, these normal foods also contain fats and other ingredients like fibers and protein, some of which slow down digestion and otherwise interfere with the necessary shift in the balance of amino acids in the blood.
- the present invention provides novel carbohydrate compositions that are rapidly digested and reduce the incidence of weight gain and/or obesity resulting from the use of psychotropic compounds.
- the invention is therefore directed generally to novel therapeutic compositions comprising rapidly-digestible carbohydrate blends, and to methods of using same for the treatment, prevention, amelioration, or dietary management of weight problems.
- Administration of a composition according to the method of the present invention is of great benefit to those who experience disturbances of mood and/or appetite and who accordingly are treated with psychotropic drugs and consequently develop weight problems.
- It is a further object of the present invention to provide therapeutic compositions comprising novel blends of carbohydrates, such as, but not limited to, dextrose, galactose, pre-gelatinized starch, mannose, sucrose, maltose, lactose, dextrin, maltodextrin, and mixtures thereof, wherein they contain no more than 1-2 grams of fat, and preferably are essentially fat free.
- carbohydrates such as, but not limited to, dextrose, galactose, pre-gelatinized starch, mannose, sucrose, maltose, lactose, dextrin, maltodextrin, and mixtures thereof, wherein they contain no more than 1-2 grams of fat, and preferably are essentially fat free.
- compositions including carbohydrate blends comprising about 20-200 g of a rapidly-digestible carbohydrate blend in a solution essentially free of protein, wherein the solution comprises a ratio of about 3-12 mL water to about 1 gram carbohydrate' blend and an acidulant selected from the group consisting of adipic acid, citric acid, fumaric acid, lactic acid, succinic acid, tartaric acid, ascorbic acid, acetic acid, and malic acid, to maintain a therapeutically effective pH at less than 6 and wherein the carbohydrate blend comprises about 60-100% dextrose, dextrin, maltodextrin, or a mixture thereof, and 0 to 40% starch or pre-gelatinized starch, or a mixture thereof.
- carbohydrate blends comprising about 20-200 g of a rapidly-digestible carbohydrate blend in a solution essentially free of protein, wherein the solution comprises a ratio of about 3-12 mL water to about 1 gram carbohydrate' blend and
- carbohydrate blends in the form of a solution comprising dextrose, starch and water.
- the solution comprises about 2-10 mL of water to 1 gram of carbohydrate blend. More preferably, the solution comprises about 5-6 mL water to 1 gram of carbohydrate blend.
- acidulants include, but are not limited to, adipic acid, citric acid, fumaric acid, lactic acid, succinic acid, tartaric acid, ascorbic acid, acetic acid, and malic acid.
- Such methods comprise administering a therapeutically effective amount of said novel compositions to subjects in need of such treatment.
- useful agents such as but not limited to vitamins; tryptophan, 5-hydroxytryptophan, tyrosine, and other amino acids; ovarian hormones; detoxifying agents and/or diuretics.
- the present invention is directed to compositions and methods for effecting weight loss and/or preventing weight gain associated with the use of psychotropic drugs such as those affecting serotonin mediated neurotransmission, including drugs that act directly upon the receptors, as well as drugs that reduce the rate of firing of the serotonin neurons. More specifically, the invention is applicable in situations when drugs affecting serotonin-mediated neurological networking and transmission are involved.
- the present invention is directed towards assisting individuals that are taking, or are planning on taking psychotropic drugs, wherein the psychotropic drugs result in the individual's having lower-than-normal serotonin-mediated neurotransmission, thus encompassing either lower than normal amounts of serotonin inside the synapses, or a decreased ability of that serotonin to combine with its receptors.
- the neurotransmitter serotonin (5-hydroxytryptamine or 5-HT) is 3-(beta- aminoethyl)-5-hydroxyindole. It stimulates or inhibits a variety of smooth muscles and nerves and, among others, has effects on secretion by both exocrine and endocrine glands and on functioning of the respiratory, cardiovascular and central nervous systems.
- serotonin serves as a neurotransmitter in the brain and spinal cord, where it is the chemical transmitter of neurons referred to as tryptaminergic or serotoninergic neurons. These neurons are involved in control of sleep, appetite, nutrient selection, blood pressure, mood, endocrine secretion, aggressivity and numerous other sensitivities to external stimuli.
- the present invention comprises the treatment, inhibition, and/or amelioration of weight gain resulting from the administration of psychotropic drugs such as "classic" psychotropic drugs, including but not limited to haliperidole, thorazine and the like, or newer “atypical” antipsychotics including but not limited to clozapine, olanzapine, or risperidone; anti-depressant drugs including but not limited to serotonin re-uptake inhibitors such as Prozac, Zoloft, and Paxil; monoamine oxidase inhibitors and tricyclics such as nortryptiline and imipramine; anti-manic drugs such as lithium; anti-epileptic drugs such as depakote and valproic acid; agents used to treat anxiety, panic disorder and obsessive-compulsive disorder; as well as illegal psychotic drugs such as cocaine, heroin, marijuana and the like.
- psychotropic drugs such as "classic" psychotropic drugs, including but not limited to haliperid
- the present invention comprises the treatment or inhibition of weight gain resulting from the administration of antipsychotics including but not limited to atypical antipsychotics, anti-epileptic medications, and medications for the treatment of bipolar manic depressive diseases.
- Atypical antipsychotics include but are not limited to clozapine, olanzapine, loxapine, molindone, resperidone, and thiothixine.
- Anti-epileptic, bi-polar and related medications include but are not limited to lithium, valproic acid, divalproex sodium, gabapentin, felbamate, and carbamazepine.
- the terms “subject”, “individual”, and “patient” may be used interchangeably to refer to a human exhibiting weight problems.
- the composition is a snack food that is comprised of complex and/or simple carbohydrates, and is substantially free of protein.
- carbohydrate encompasses both complex carbohydrates and simple sugars.
- the carbohydrate is of a high glycemic index, such as maltodextrin, polycose (a synthetic polyglucose), dextrose, sucrose, maltose, to name a few.
- Other sources of carbohydrate include but are not limited to, galactose, pre-gelatinized starch, mannose, lactose, dextrin, and mixtures of the above. Rapidly digestible blends of carbohydrate can likewise be used.
- protein includes any high quality protein derived from an animal or plant source, and does not include basic amino acids, amino acid derivatives, or small peptides. Proteins derived from animal foods such as dairy products or eggs are suitable, including, but not limited to, whey, casein, or albumin.
- the snack food can be further comprised of additional ingredients including, but not limited to, sources of fat, fiber, calcium, and other vitamins and minerals.
- the composition provided is preferably low in fat, however, with preferably less than 20% of the calories provided in the composition deriving from fat.
- the amount of fiber, such as methylcellulose can also be adjusted, but preferably provides between about 20-25 grams of fiber per day.
- compositions of the present invention can be provided in any convenient form, including but not limited to powders, liquids, soups, food bars, pudding, and milk shakes. Natural and/or artificial flavorings can also be added, including the following flavors: chocolate, vanilla, strawberry, apple, ram, banana, orange, mocha, etc. As stated, in its preferred embodiment, the composition is a snack food.
- the snack food should elevate the Tp/Lnaa ratio relative to the pre- consumption levels.
- the post-consumption plasma Tp/Lnaa ratio is elevated relative to the pre-consumption plasma Tp/Lnaa ratio by about 10% or more, more preferably by 15% or more, most preferably by about 20% to about 30% or more.
- the snack food comprises at least one form of carbohydrate and is substantially free of protein.
- the snack food can include complex carbohydrates, simple sugars or both.
- the snack food has a caloric content ranging from about 50 to about 500 calories, preferably, from about 175 to about 225 calories, and most preferably, from about 200 to about 225 calories.
- Its protein content is preferably substantially zero.
- Its carbohydrate content can range from about 20 to about
- the snack food of the present invention can also provide about 0 to about 5 grams of fat, preferably, about 0 to about 3 grams, most preferably, about 1-2 grams, and about 0 to about 20 grams of fiber, preferably, about 1 to about 15, and most preferably, about 5 to about 10 grams.
- the carbohydrates used in the present invention should preferably have a glycemic index higher than fructose. Suitable carbohydrates (CHO) include, but are not limited to, dextrose, sucrose, maltose, maltodextrin or polycose.
- a number of compounds stimulate or enhance serotonin-mediated neurotransmission are thus useful in extending the beneficial effect obtained through the administration of the carbohydrate containing composition; e.g. the snack food.
- the compounds can be added to the carbohydrate composition, or can be administered as a second composition.
- This second composition can be administered either prior to, concurrently or after the carbohydrate composition.
- Preferably the second composition is administered within one hour after administration of the carbohydrate composition.
- these compounds include D,L-fenfluramine, dexfenfluramine, tryptophan, melatonin and pharmaceutically acceptable salts thereof.
- Suitable salts can be formed from the above compounds, for example, as addition salts using the following acids: inorganic acids such as hydrochloric acid, sulfuric acid, and phosphoric acid or organic acids such as acetic acid, maleic acid, valeric acid, caproic acid, benzoic acid and nicotinic acid.
- inorganic acids such as hydrochloric acid, sulfuric acid, and phosphoric acid
- organic acids such as acetic acid, maleic acid, valeric acid, caproic acid, benzoic acid and nicotinic acid.
- Fenfluramines is used in the present application as meaning a racemic mixture of D,L-fenfluramine, which is also called N-ethyl- ⁇ -methyl-3-(trifluoro- methyl)benzeneethanamine; the dextrorotatory isomer known as dexfenfluramine and also as D-fenfluramine; or the pharmaceutically acceptable salts of these compounds.
- Suitable salts can be formed from dexfenfluramine or D-L-fenfluramine, for example, as addition salts using the following acids: inorganic acids such as hydrochloric acid, sulfuric acid, and phosphoric acid or organic acids such as acetic acid, maleic acid, valeric acid, caproic acid, benzoic acid and nicotinic acid.
- inorganic acids such as hydrochloric acid, sulfuric acid, and phosphoric acid
- organic acids such as acetic acid, maleic acid, valeric acid, caproic acid, benzoic acid and nicotinic acid.
- 6-Chloro-2-(l-piperazinyl)pyrazine (MK-212), can be obtained from Merck & Co., Inc. Whitehouse Station, NJ.
- (S)-2-(4, 4, 7-trimethyl-l, 4-dihydro-indeno (1, 2-B) pyrrol- l-yl-)-l-methyl-ethylamine (Ro 60-175/ORG 35030) can be obtained from F. Hoffmann-LaRoche Ltd., Basel, Switzerland.
- (S)-2-(Chloro-5-fluoro-indol-l-yl)-l- methylethylamine (Ro 60-0332/ORG 35035) is obtained from F. Hoffmann LaRoche Ltd., Basel, Switzerland.
- l-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane can be obtained from Research Biochemical International, Natick, MA.
- l-(3- Chlorophenyl)piperazine m-CPP
- L-TP L-tryptophan
- L-5-HTP L-5-hydroxytryptophan
- the supplementation of precursors for serotonin comprises administering, for an effective period, an effective amount of L-tryptophan or preferably L-5- hydroxytryptophan as the intermediate precursors for serotonin (5-hydroxytryptamine). It is understood that any of its L, D or racemic forms are suitable, but preferably precursors are in L form.
- tryptophan from 3- indolacetic acid or 3-indolpyruvic acid or use these acids as alternative to tryptophan and thus avoid the hepatic degradation by tryptophan pyrrolase.
- serotonin precursors can be administered alone or in combination with the stimulants of serotonin synthesis including but not limited to vitamin Bl, vitamin B3, vitamin B6, biotin, S-adenosylmethionine, folic acid, ascorbic acid, magnesium, coenzyme Q10, and piracetam.
- serotoninergic drags that act as serotonin agonists including but not limited to ergolide mesylate, pergolide mesylate, buspirone, (3beta)-2,3-dihydrolysergine, (3beta)-2,3- dihydroisolysergine, (3beta)-2,3-dihydrolysergol, (3beta)-2,3-dihydrolysergene, (3beta, 5beta, 8beta)-9,10-didehydro-2,3-dihydro-6-methyl-8-(methylthiomethyl) ergoline, (3beta, 5beta, 8beta)-9,10-didehydro-2,3-dihydro-6-methylergoline-8-ac etonitrile, (3beta, 5beta, 8beta)-9, 10-didehydiO-2,3
- the active serotonin-mediated neurotransmission stimulating compound can be administered to a patient as a pharmaceutical composition comprising the active compound admixed with a pharmaceutically acceptable carrier, including one or more excipients.
- the compound or precursor can be administered to a patient as a pharmaceutical composition comprising in a preferred embodiment either L-tryptophan or L-5-hydroxytryptophan admixed with a pharmaceutically acceptable carrier, including one or more excipients.
- the invention can be practiced by administering serotonin-mediated neurotransmission stimulating compounds, for example, tryptophan or 5-hydroxytryptophan, to a subject as a single unit dose one or more times per day, or as a plurality of unit doses once or more times per day without deviating from the teachings of the invention.
- serotonin-mediated neurotransmission stimulating compounds for example, tryptophan or 5-hydroxytryptophan
- the present invention as disclosed herein, also includes a method of making a medicament for treating and/or inhibiting weight gain resulting from the use of psychotropic drugs, wherein the method comprises a step of mixing a serotonin precursor such as tryptophan or 5-hydroxytryptophan with a pharmaceutically acceptable inert ingredient.
- a serotonin precursor such as tryptophan or 5-hydroxytryptophan
- compositions of this invention are suitable for oral, parenteral, buccal, sublingual or rectal administration.
- the resulting pharmaceutical compositions are, for example, tablets, coated tablets, capsules, soft gelatin capsules, drinkable emulsions, suspensions or solutions for oral or injectable administration, sublingual tablets or suppositories. They can also be formulated into a sustained release form.
- excipients which can be used for these purposes include talc, magnesium phosphate, lactose or silica or the like.
- compositions of this invention can also be flavored, colored or coated with a wax or a plasticizer.
- compositions of this invention can also be administered through sachets to which the subject adds water, or as a food based preparation, functional food, dietary supplement or nutraceutical.
- functional food is defined as a food engineered or supplemented to give improved nutritional value
- dietary supplement is defined as a substance produced by isolation, or microbial culture purification that gives health benefits
- nutraceutical is defined as a food, or parts of a food, that provide medical or health benefits, including prevention and treatment of clinical conditions and/or symptoms related thereto.
- compositions of this invention can also be isolated from varying plants or components thereof including but not limited to root, tuber, rind/peel, bark, seed, fruit, bulb, flower, rhizome, leaf, stem, oil, shell, capsule, twig, resin, extract, and bean.
- the aforementioned components can be consumed by the subject, thereby providing the subject with the active ingredient(s) of the invention disclosed herein.
- an effective dose ranges from about 20 mg to about 4 g/day, preferably from about 50 mg to about 1 g/day, more preferably about 50 mg to about 400 mg/day, and most preferably about 100 mg/day. As stated, this administration can be concurrent with, or subsequent to, administration of the carbohydrate blend composition. The following examples are further provided. 6. EXAMPLES
- composition is a carbohydrate blend of the present invention.
- the composition ingredients are all generally recognized as safe (GRAS) without limitations; the compositions themselves are therefore also GRAS; and the compositions are formulated in full compliance with all good manufacturing practice. regulations of the Food and Drag Administration (FDA).
- carbohydrate compositions include but are not limited to: (1) 44.5 g of dextrose, 3 g starch, 1.4 g malic acid, pH 2, 270 mL water, orange flavoring; (2) 60 g dextrose, pH 5, 180 mL water; (3) 60g dextrose, pH 2, 360 mL water; and (4) 30g dextrose, pH 2, 360 mL water.
- Blood samples are obtained from subjects at various times before and after consumption of carbohydrate blends of the present invention to determine the ratio of T:LNAA.
- Subjects administered with carbohydrate blends of the present invention have a T:LNAA ratio of 0.217 ⁇ 0.025 after ingestion compared with a 0.168 ⁇ 0.016 pre- ingestion measurements and compared with carbohydrate blends containing proteins and other constituents. Further, there is an earlier onset and greater increase of T:LNAA using blends of the present invention over normal carbohydrates (bagel, juice, or potato).
- Carbohydrate blends of present invention or a placebo solution are tested in subjects suffering from weight gain due to psychotropic drug use.
- a woman of 73 gained about 60 pounds from long term treatment with Prozac. After about nine months on the instant diet she looses approximately 40 pounds while still being on anti-depressant therapy. Due to orthopedic problems she is immobile and weight loss cannot be attributed to any physical exercise or any other activities or treatments. The eating habits are now under control and craving for carbohydrates is ceased.
- compositions of the present invention comprising novel carbohydrate blends inhibit weight gain and promote weight loss.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001243369A AU2001243369A1 (en) | 2000-03-14 | 2001-03-02 | Composition and method to treat weight gain and obesity attributable to psychotropic drugs |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52505800A | 2000-03-14 | 2000-03-14 | |
US09/525,058 | 2000-03-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001067890A2 true WO2001067890A2 (en) | 2001-09-20 |
WO2001067890A3 WO2001067890A3 (en) | 2002-02-07 |
Family
ID=24091738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/006637 WO2001067890A2 (en) | 2000-03-14 | 2001-03-02 | Composition and method to treat weight gain and obesity attributable to psychotropic drugs |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2001243369A1 (en) |
WO (1) | WO2001067890A2 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005025563A1 (en) * | 2003-09-12 | 2005-03-24 | Warner-Lambert Company Llc | Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders |
CN1299681C (en) * | 2005-08-29 | 2007-02-14 | 陈彦方 | Health caring formulation for treating insomnia |
WO2007017139A1 (en) * | 2005-07-29 | 2007-02-15 | Tima Foundation | Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases |
WO2007016950A1 (en) * | 2005-07-29 | 2007-02-15 | Matuschka-Greiffenclau Markus | Composition for reducing the risk of alcohol induced neurodegenerative disease |
WO2007016949A1 (en) * | 2005-07-29 | 2007-02-15 | Matuschka-Greiffenclau Markus | Composition for reducing the risc of alcohol induced neuropathy |
US20110251290A1 (en) * | 2006-10-25 | 2011-10-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Treatment of hepatic encephalopathy and liver cirrhosis |
US10519175B2 (en) | 2017-10-09 | 2019-12-31 | Compass Pathways Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11564935B2 (en) | 2019-04-17 | 2023-01-31 | Compass Pathfinder Limited | Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0007691A1 (en) * | 1978-07-31 | 1980-02-06 | Massachusetts Institute Of Technology | Compositions for use in decreasing appetite for calories as carbohydrates |
US4497800A (en) * | 1982-07-06 | 1985-02-05 | Mead Johnson & Company | Stable liquid diet composition |
WO1996039868A1 (en) * | 1995-06-07 | 1996-12-19 | Massachusetts Institute Of Technology | Composition and methods for losing weight |
-
2001
- 2001-03-02 AU AU2001243369A patent/AU2001243369A1/en not_active Abandoned
- 2001-03-02 WO PCT/US2001/006637 patent/WO2001067890A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0007691A1 (en) * | 1978-07-31 | 1980-02-06 | Massachusetts Institute Of Technology | Compositions for use in decreasing appetite for calories as carbohydrates |
US4497800A (en) * | 1982-07-06 | 1985-02-05 | Mead Johnson & Company | Stable liquid diet composition |
WO1996039868A1 (en) * | 1995-06-07 | 1996-12-19 | Massachusetts Institute Of Technology | Composition and methods for losing weight |
Non-Patent Citations (2)
Title |
---|
NOBREGA J N ET AL: "EFFECTS OF CHRONIC AMITRIPTYLINE AND DESIPRAMINE ON FOOD INTAKE AND BODY WEIGHT IN RATS" PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, vol. 27, no. 1, 1987, pages 105-112, XP001030528 ISSN: 0091-3057 * |
RUSS M J ET AL: "L TRYPTOPHAN DOES NOT AFFECT FOOD INTAKE DURING RECOVERY FROM DEPRESSION" INTERNATIONAL JOURNAL OF EATING DISORDERS, vol. 10, no. 5, 1991, pages 539-546, XP001030530 ISSN: 0276-3478 * |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005025563A1 (en) * | 2003-09-12 | 2005-03-24 | Warner-Lambert Company Llc | Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders |
WO2007017139A1 (en) * | 2005-07-29 | 2007-02-15 | Tima Foundation | Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases |
WO2007016950A1 (en) * | 2005-07-29 | 2007-02-15 | Matuschka-Greiffenclau Markus | Composition for reducing the risk of alcohol induced neurodegenerative disease |
WO2007016949A1 (en) * | 2005-07-29 | 2007-02-15 | Matuschka-Greiffenclau Markus | Composition for reducing the risc of alcohol induced neuropathy |
EA012753B1 (en) * | 2005-07-29 | 2009-12-30 | Тима Фаундейшн | Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases |
US8580750B2 (en) | 2005-07-29 | 2013-11-12 | Tima Foundation | Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases |
US9402849B2 (en) | 2005-07-29 | 2016-08-02 | Tima Foundation | Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases |
CN1299681C (en) * | 2005-08-29 | 2007-02-14 | 陈彦方 | Health caring formulation for treating insomnia |
US20110251290A1 (en) * | 2006-10-25 | 2011-10-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Treatment of hepatic encephalopathy and liver cirrhosis |
US10166202B2 (en) * | 2006-10-25 | 2019-01-01 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Treatment of hepatic encephalopathy and liver cirrhosis |
US10519175B2 (en) | 2017-10-09 | 2019-12-31 | Compass Pathways Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US10947257B2 (en) | 2017-10-09 | 2021-03-16 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US10954259B1 (en) | 2017-10-09 | 2021-03-23 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11149044B2 (en) | 2017-10-09 | 2021-10-19 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11180517B2 (en) | 2017-10-09 | 2021-11-23 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11447510B2 (en) | 2017-10-09 | 2022-09-20 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11505564B2 (en) | 2017-10-09 | 2022-11-22 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11629159B2 (en) | 2017-10-09 | 2023-04-18 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11851451B2 (en) | 2017-10-09 | 2023-12-26 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11939346B2 (en) | 2017-10-09 | 2024-03-26 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
US11564935B2 (en) | 2019-04-17 | 2023-01-31 | Compass Pathfinder Limited | Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
US11738035B2 (en) | 2019-04-17 | 2023-08-29 | Compass Pathfinder Limited | Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
Also Published As
Publication number | Publication date |
---|---|
WO2001067890A3 (en) | 2002-02-07 |
AU2001243369A1 (en) | 2001-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Silverstone et al. | Serotoninergic mechanisms in human feeding: the pharmacological evidence | |
US6579899B1 (en) | Composition for treatment of stress | |
JP2925326B2 (en) | Methods for promoting human nitrogen retention | |
US7115285B2 (en) | Composition and method for appetite and craving suppression and mood enhancement | |
US9700548B2 (en) | Antihistamines combined with dietary supplements for improved health | |
JP5854918B2 (en) | Effect of uridine on dopamine release. | |
US20220133741A1 (en) | AAntihistamines In Combination With A Range Of Substances For Improved Health | |
DK2644198T3 (en) | ANTIANXIETY AND SLEEP DISORDER IMPROVING USE OF ALBIFLORIN | |
WO2001067890A2 (en) | Composition and method to treat weight gain and obesity attributable to psychotropic drugs | |
Rivera-García et al. | The Resurgence of Hallucinogen Drugs in Clinical Research | |
JPH01500030A (en) | Use of growth hormone for nitrogen retention in hypocaloric conditions | |
Heraief et al. | Tryptophan administration may enhance weight loss by some moderately obese patients on a protein‐sparing modified fast (PSMF) diet | |
JP2005524629A (en) | Jojoba products for reducing body weight, blood lipid levels and for cancer prevention and treatment | |
US11766458B2 (en) | Method and a dietary composition on regulation, treatment, and prevention of obesity | |
US20230023788A1 (en) | Method and a dietary composition on regulation, treatment, and prevention of obesity | |
Trygstad | Drugs in the treatment of bulimia nervosa | |
US20230024207A1 (en) | Method and a dietary composition on regulation, treatment, and prevention of obesity | |
Blackwell et al. | Antidepressant drugs | |
CN100408038C (en) | Use of a vitamin combination for the treatment of primary headaches | |
KR20120055159A (en) | A composition for reducing sleep induction time and prolonging sleeping time containing chrysanthemum indicum extract, and preparing method for the same | |
US20190008188A1 (en) | Antihistamines Combined with Dietary Supplements for Improved Health | |
Lakhan et al. | Nutritional supplements and sleep: an overview | |
US20140178507A1 (en) | Weight management composition | |
US20060122261A1 (en) | [method of preparing labdane diterpene composition, preferably isoforskolin and deacetylforskolin from forskolin extract and their use for promoting lean body mass and other applications] | |
CN114766670A (en) | Special dietary food formula with sleep-aiding function |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |